Revive Therapeutics — Fact Sheet (March 2023)

2 slides from Revive Therapeutics's fact sheet, Mar 24, 2023

Slide 1: Corporate Fact Sheet 1H-2023
Corporate Fact Sheet 1H-2023 OVERVIEW  Focus on repurposing drugs for rare & infectious diseases  Awarded FDA Orphan Drug Status for CBD in the  Advancing clinical development of Bucillamine for treatment of Autoimmune Hepatitis infectious diseases, including COVID-19 (FDA Phase 3)  Prioritize d
Slide 2: Slide 2